Hisun Pharmaceutical Exports Fluvastatin To Europe
This article was originally published in PharmAsia News
Executive Summary
Hisun Pharmaceutical shipped 900,000 fluvastatin capsules to Europe in November. It is the first China enterprise to cooperate with an overseas partner to enter the EU under its branded pharmaceutical formulation. Hisun collaborates with a German drug manufacturer to apply for European pharmaceutical certifications for its fluvastatin formulation and received approval in August. Even though the fluvastatin export will not contribute substantially to the firm's profit in the short term, it paves the way for Hisun's strategic shift from the production of active pharmaceutical ingredients to higher value-added co-development of APIs and formulations. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.